Moderna's personalized melanoma vaccine just posted positive late-stage results alongside Merck, yet shares keep sliding ...
Zacks Investment Research on MSN
Here is what to know beyond why Merck & Co., Inc. (MRK) is a trending stock
Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the ...
Merck stock looks fairly valued as Keytruda risks, slower EPS growth, and debt weigh on upside. Click here to read an ...
A Growing Franchise With an Expiration Date Merck & Co., Inc. (NYSE:MRK) is trying to extend its oncology leadership before ...
Shares of Moderna Inc. and Merck & Co. fell after reports emerged about the results of the companies’ widely anticipated ...
His comments come after Merck officially opened its new 120,000-square-foot research facility in the Greater Philadelphia ...
Rahway, New Jersey-based Merck & Co., Inc. (MRK) is an international healthcare company that offers human health ...
A combination of the personalized cancer vaccine intismeran autogene and Merck's Keytruda just barely cleared analysts’ ...
Merck & Co. and Moderna always knew they would be making headlines in Madrid this week—just not in the way it panned out. | Merck & Co. and Moderna always knew they would be making headlines in Madrid ...
Merck KGaA agreed to acquire Silence Therapeutics Plc for about $1.1 billion in a cash transaction as the German science ...
Germany’s Merck KGaA has agreed to acquire British biotechnology company Silence Therapeutics for approximately $1.3 billion ...
Merck trades at a single-digit P/E, reflecting underperformance but strong financials and a robust dividend yield near 3.9%. Keytruda’s ongoing success and expanded indications drive near-term results ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results